cemiplimab + S095018

Cemiplimab + S095018 is an investigational combination therapy under evaluation in advanced/metastatic non-small cell lung cancer (NSCLC) with high PD-L1 expression. Cemiplimab is a fully human IgG4 monoclonal antibody that targets and inhibits **programmed cell death protein 1 (PD-1)**, enhancing anti-tumor immune responses. S095018 is a monoclonal antibody targeting **T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3)**, an immunoregulatory receptor involved in immune exhaustion and resistance to anti-PD-1/PD-L1 therapy. The combination aims to overcome immune resistance and improve efficacy compared to anti-PD-1 therapy alone. This combination is delivered via intravenous infusion and is developed and sponsored by Regeneron Pharmaceuticals (cemiplimab) and Institut de Recherches Internationales Servier (S095018). Current clinical studies are in Phase 1b/2 for first-line treatment of advanced/metastatic NSCLC with high PD-L1 expression[1][2][3][4][5][7].